enGene Holdings Inc. Common Stock Total Liabilities
enGene Holdings Inc. Common Stock total liabilities. Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has total liabilities worth $58.03 Million USD as of July 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check enGene Holdings Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of enGene Holdings Inc. Common Stock (2021–2025)
Total liabilities of enGene Holdings Inc. Common Stock from 2021 to 2025. This chart illustrates how enGene Holdings Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore enGene Holdings Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
enGene Holdings Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DAE-IL Corporation
KO:092200
|
Korea | ₩538.96 Billion |
|
Monte Carlo Fashions Limited
NSE:MONTECARLO
|
India | Rs-9.06 Billion |
|
Icon Group
TA:ICON
|
Israel | ILA364.43 Million |
|
ADDvise Group B
ST:ADDV-B
|
Sweden | Skr1.81 Billion |
|
Cape Industries Ltd
KQ:064820
|
Korea | ₩4.26 Trillion |
|
Bank Negara Indonesia Tbk
JK:BBNI
|
Indonesia | Rp1036.47 Trillion |
|
Rentokil Initial PLC
LSE:RTO
|
UK | GBX6.81 Billion |
|
Kuang Hong Arts Management
TWO:6596
|
Taiwan | NT$969.97 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down enGene Holdings Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see enGene Holdings Inc. Common Stock balance sheet assets.
Liquidity & Leverage Metrics
enGene Holdings Inc. Common Stock Total Liabilities Ratios Explained
enGene Holdings Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how enGene Holdings Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of enGene Holdings Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $53.76 Million | +39.41% |
| 2024-10-31 | $38.56 Million | +166.43% |
| 2023-10-31 | $14.47 Million | +213.20% |
| 2022-10-31 | $4.62 Million | +13.96% |
| 2021-10-31 | $4.05 Million | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more